CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone

CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone
CVRx unveils Barostim at ACC26

CVRx is promoting its Barostim device at #ACC26, emphasizing the treatment's ability to enhance exercise capacity and quality of life for heart failure patients where guideline-directed medical therapy (GDMT) alone falls short.

The Barostim system targets the neurohormonal pathway and is presented as a novel solution for patients seeking better outcomes beyond standard medical treatment. Attendees of the conference are invited to learn more about the technology and its potential impact on managing heart failure.

CVRx recently joined Orlando Health South Lake Hospital to deliver its first Barostim implant, aiming to improve heart failure patient care. Earlier this year, the company opened THT2026 with late-breaking data and real-world results demonstrating Barostim’s impact on cardiovascular outcomes. These developments follow growing industry attention to Barostim’s potential in treating heart failure.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.